SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI


Por: Metra, M, Tomasoni, D, Adamo, M, Amir, O, Anker, SD, Bayes-Genis, A, Boehm, M, Butler, J, Chioncel, O, Filippatos, G, Gustafsson, F, Jankowska, EA, Kaski, JC, Moura, B, Petrie, MC, Ponikowski, P, Rakisheva, A, Ristic, A, Roubille, F, Savarese, G, Seferovic, P, van der Meer, P, Volterrani, M, Coats, AJ, Chopra, VK and Rosano, G

Publicada: 1 dic 2025 Ahead of Print: 1 sep 2025
Resumen:
In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium-glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF). Further trials showed efficacy of empagliflozin and dapagliflozin in patients with HF with preserved ejection fraction (HFpEF). These results prompted a broadened recommendation for the SGLT2 inhibitors dapagliflozin or empagliflozin across the whole left ventricular ejection fraction (LVEF) spectrum in the 2023 Focused Update of the ESC HF guidelines and in other international guidelines. In SOLOIST-WHF and EMPULSE, sotagliflozin (enrolling only patients with T2DM) and empagliflozin, respectively, were beneficial when initiated at the end or soon after an episode of decompensated HF. Based on these results and on the early appearance of their beneficial effects, the administration of SGLT2 inhibitors should start early in patients hospitalized for acute HF. Analyses after study drug withdrawal in randomized clinical trials have shown that their benefits may decline rapidly after discontinuation, and thus, persistence of treatment is advised. In EMPACT-MI, empagliflozin did not reduce the primary outcome of cardiovascular (CV) death/HF hospitalization but reduced first/recurrent HF hospitalizations. Potential benefits of SGLT2 inhibitors in further specific conditions (i.e., cardiac amyloidosis, grown-up congenital heart disease and paediatric patients with HF) have been reported in observational studies but need confirmation from prospective trials. This scientific statement summarizes current evidence regarding the effects of SGLT2 inhibitors for the prevention and treatment of HF.

Filiaciones:
Metra, M:
 Univ Brescia, ASST Spedali Civili Brescia, Cardiol, Brescia, Italy

 Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy

Tomasoni, D:
 Univ Brescia, ASST Spedali Civili Brescia, Cardiol, Brescia, Italy

 Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy

 Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden

Adamo, M:
 Univ Brescia, ASST Spedali Civili Brescia, Cardiol, Brescia, Italy

 Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Brescia, Italy

Amir, O:
 Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Dept Cardiol, Jerusalem, Israel

Anker, SD:
 Charite Univ Med Berlin, Dept Cardiol CVK, German Ctr Cardiovasc Res DZHK, German Heart Ctr Charite,Partner Site Berlin, Berlin, Germany

:
 Hosp Badalona Germans Trias & Pujol, Heart Inst, CIBERCV, Badalona, Barcelona, Spain

Boehm, M:
 Saarland Univ, Klin Innere Med 3, Univ Klinikum Saarlandes, Homburg, Germany

Butler, J:
 Baylor Scott & White Res Inst, Dallas, TX USA

 Univ Mississippi, Jackson, MS USA

Chioncel, O:
 Univ Med & Pharm Carol Davila, Emergency Inst Cardiovasc Dis Prof CC Iliescu, Bucharest, Romania

Filippatos, G:
 Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

Gustafsson, F:
 Univ Copenhagen, Heart Ctr, Dept Cardiol, Rigshosp, Copenhagen, Denmark

Jankowska, EA:
 Wroclaw Med Univ, Inst Heart Dis, Wroclaw, Poland

Kaski, JC:
 St Georges Univ London, Mol & Clin Sci Res Inst, London, England

Moura, B:
 Ctr Invest Tecnol & Serv Saude, Porto, Portugal

 Hosp Forcas Armadas Polo Porto, Serv Cardiol, Porto, Portugal

Petrie, MC:
 Univ Glasgow, Sch Cardiovasc & Metab Hlth, Glasgow City, England

Ponikowski, P:
 Wroclaw Med Univ, Inst Heart Dis, Wroclaw, Poland

 Wroclaw Med Univ, Dept Cardiol, Wroclaw, Poland

Rakisheva, A:
 Sci Inst Cardiol & Internal Dis, Dept Cardiol, Alma Ata, Kazakhstan

Ristic, A:
 Univ Belgrade, Sch Med, Belgrade, Serbia

Roubille, F:
 Univ Montpellier, Cardiol Dept, CHU Montpellier, PhyMedExp,INSERM,CNRS, Montpellier, France

Savarese, G:
 Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Stockholm, Sweden

Seferovic, P:
 Serbian Acad Arts & Sci, Belgrade, Serbia

van der Meer, P:
 Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands

Volterrani, M:
 IRCCS San Raffaele Pisana, Ctr Clin & Basic Res, Dept Med Sci, Rome, Italy

Coats, AJ:
 Heart Res Inst, Newtown, NSW, Australia

Chopra, VK:
 Medanta, Dept Cardiol, Gurgaon, Haryana, India

Rosano, G:
 San Raffaele Open Univ Rome, Dept Human Sci & Promot Qual Life, Rome, Italy

 IRCCS San Raffaele, Rome, Italy
ISSN: 20555822





ESC Heart Failure
Editorial
The Heart Failure Association of the European Society of Cardiology, ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA, Reino Unido
Tipo de documento: Review
Volumen: 12 Número: 6
Páginas: 3806-3825
WOS Id: 001574402100001
ID de PubMed: 40968746
imagen Green Accepted, Green Submitted, gold

MÉTRICAS